{
    "id": "2c0e145b-96b0-4f7b-8993-0f5f59afa81d",
    "indications": {
        "text": "eribulin mesylate injection microtubule inhibitor indicated treatment patients : \u00b7 metastatic breast cancer previously received least two chemotherapeutic regimens treatment metastatic disease . prior therapy included anthracycline taxane either adjuvant metastatic setting . ( 1.1 ) \u00b7 unresectable metastatic liposarcoma received prior anthracycline-containing regimen . ( 1.2 )",
        "doid_entities": [
            {
                "text": "breast cancer (DOID:1612)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1612"
            },
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "liposarcoma (DOID:3382)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3382"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u00b7 administer 1.4 mg/m2 intravenously 2 5 minutes days 1 8 21-day cycle . ( 2.1 ) \u00b7 reduce dose patients hepatic impairment moderate severe renal impairment . ( 2.1 ) \u00b7 mix drugs administer dextrose-containing solutions . ( 2.3 )",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "severe renal impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "injection : 1 mg/2 ml , single-dose vial . one vial per carton\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 ndc 70095-080-01 store 20\u00ba 25\u00bac ( 68\u00ba 77\u00baf ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] . freeze refrigerate . store vials original cartons . eribulin mesylate injection colorless clear liquid . eribulin mesylate injection cytotoxic . follow applicable special handling disposal procedures.\u00b9",
    "adverseReactions": "none .",
    "ingredients": [
        {
            "name": "ERIBULIN MESYLATE",
            "code": "AV9U0660CW",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_70710"
        },
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        }
    ],
    "organization": "Sun Pharmaceutical Industries Limited",
    "name": "ERIBULIN MESYLATE",
    "effectiveTime": "20250506",
    "indications_original": "Eribulin mesylate injection is a microtubule inhibitor indicated for the treatment of patients with: \u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.\u00a0(1.1) \u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.\u00a0(1.2)",
    "contraindications_original": "\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Administer 1.4 mg/m2 intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle.\u00a0(2.1) \u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Reduce dose in patients with hepatic impairment or with moderate or severe renal impairment. (2.1) \u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Do not mix with other drugs or administer with dextrose-containing solutions. (2.3)",
    "warningsAndPrecautions_original": "Injection: 1 mg/2 mL, in a single-dose vial. One vial per carton\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 NDC 70095-080-01\n                  \n                  Store at 20\u00ba to 25\u00baC (68\u00ba to 77\u00baF); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [See USP Controlled Room Temperature]. Do not freeze or refrigerate. Store the vials in their original cartons.\n                  \n                  Eribulin mesylate injection is colorless and clear liquid.\n                  \n                  Eribulin mesylate injection is a cytotoxic drug. Follow applicable special handling and disposal procedures.\u00b9",
    "adverseReactions_original": "None.",
    "drug": [
        {
            "name": "ERIBULIN MESYLATE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_70710"
        }
    ]
}